Scancell Share Discussion Threads

[marcusl2] 29/12/2021 14:37

Bermudashorts

12th Annual
Driving Clinical Success in Antibody Drug Conjugates
Creating the Magic Bullet
MAY 5 - 6, 2022 | HYNES CONVENTION CENTER, BOSTON, MA | EDT


4:20 pm
Multi-Functional, Multi-Targeting Anti-Glycan Monoclonal Antibodies


Lindy G. Durrant, PhD, CSO, Scancell Ltd.
Glycans are excellent tumor targets. Notably, the same glycan expressed on a range of glycoproteins/lipids allows mAbs to target multiple antigens some of which can internalize whilst others are retained on the cell surface. Our mAbs can be potent ADCs but also retain ADCC/CDC activity and can cause membrane perturbation resulting in direct cell lysis. Additionally, Avidimab increases the avidity of any mAb and results in improved tumor killing.

www.pegsummit.com/antibody-drug-conjugates

[marcusl2] 29/12/2021 14:37

Just into phase I

Legochem licenses out ADC to Iksuda in $1B deal
Dec. 28, 2021

[marcusl2] 29/12/2021 14:36

The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMabâ„¢ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3



Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:



"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMabâ„¢ technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy."

[panama7] 29/12/2021 14:18

Supernumerary, perhaps but I am in Colombia high 80's everyday, I have a very healthy lifestyle and all of a sudden with a very transmissable variant I get the very same symptoms that are being publicised, why would I want to take a test when I am virtually fully recovered and the tests are a catch all for anyone and everyone to bump up the numbers and add to the fear and propaganda.

[supernumerary] 29/12/2021 14:08

'what I would assume to be the Omicron variant' + 'No intention of going for a test' = the triumph of confirmation bias over common sense.

[panama7] 29/12/2021 13:59

Gecko and EE, in light of your discussion earlier on modelling I suggest you read the Spectator interview between Fraser Nelson and SAGE's Graham Medley, you will find all the answers there. No point in me posting the link as you won't see it.

[marcusl2] 29/12/2021 13:48

BOJO2020

Posts: 2,145

Price: 20.25

Strong Buy

Paul Hill29 Dec 2021 11:43
Can I make a suggestion for all you tweeters out there!

Paul Hill from VOX Markets is compiling a list of top tips for 2022! I have already replied suggesting Scancell on the basis of Covidity and it’s multiple targets (strains and Nucleocapsid).

It would be great if you could tweet a reply briefly explaining why you tip Scancell. Maybe SCIB1, Modi1 etc or all of the above!



This gets you to the article. I will leave it with you guys. VOX has a good following…

[panama7] 29/12/2021 13:43

Just had what I would assume to be the Omicron variant in the last few days. I am allegedly one of those in the at risk category. I have had common colds previously where I have been in bed for up to four days, this was far milder, spent all day in bed yesterday after first getting symptoms the day before but am well on the way to a full recovery. No intention of going for a test , will now have natural immunity not that that now stands for anything in this new Trust the Science World. If it is the mildest of colds for me than the best thing that can happen is to let it run it's course amongst the young fit and healthy and just shield those that want to be shielded.

[marcusl2] 29/12/2021 13:02

AvidiMab™ AvidiMab™ is a patent protected technology platform which increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. Tumour-associated glycans (‘TaGs’) are attractive targets as they are often exquisitely target-specific. The challenge has been to produce high affinity antibodies that are capable of recognising these interlocking sugar molecules.

Three different non-exclusive evaluation agreements have been entered into, highlighting an exceptional level of interest in the platform. Most recently, for example on 20 January 2020, Scancell announced its latest collaborative agreement with a US-based, clinical stage antibody company to assess mAbs targeting TaGs, including those that have been enhanced with Scancell's AvidiMab™ technology.

Given the broad potential it possesses to increase the avidity or potency of any therapeutic mAbs, including those being developed for autoimmune diseases as well as cancer, this offers Scancell potential future licensing opportunities. The global therapeutic mAb market that was estimated to be valued at US$150Bn in 2019.

The approach adopted by Scancell in cooperation with the University of Nottingham for its own clinical programme, includes targeting multiple tumour types (including colorectal, gastric, pancreatic, ovarian, breast and lung), identified through five mAbs glycolipid and glycoprotein cancers. Enhanced through AvidiMab™ technology and being ultraspecific to unique TaGs, the direct tumour cell killing properties of Scancell's mAbs can be achieved and induce potent ADCC/ADCP and CDC.

A summary of current studies include FG129-ADC/AvidiMabTM, an antibody-drug conjugate (‘ADC’) that internalises to liposomes in order to release the therapeutic through diffusion into the target cancer cell. The ADC has been seen to clear human tumours growing on xenographs in a nude mice in vivo study. A FG129 patent has been accepted for grant in USA and was awarded earlier this year in Europe and published in Brazil. Scancell is also in discussions with other developers to establish if AvidiMabTM supports the effectiveness of other ADCs. Elsewhere, FG27 is a pure stand-alone AvidiMabTM antibody that is seen to ‘punch’ holes in cancer cells and is being initially progressed for treatment of gastric cancer. FL134 CART binds to SCLC, a particularly aggressive condition with a poor prognosis; progression of this lab-based research into clinic is expected, however, to await identification of a suitable external collaborative partner. A fourth monoclonal antibody, FG2811, targets T-cells rather than tumour cells, in order to stimulate improved T-cell responses in cancer patients, or to target patients with auto-immune disease to inhibit Tcell over-expression. A AvidiMabTM platform is also being developed in order to improve potency of any mAb and the direct killing ability of anti-glycan mAb; investigations are presently underway to understand how broadly it might be utilised.

[geckotheglorious] 29/12/2021 13:00

EE

You know me. I want "ALL" the information to base my "personal" risk/reward analysis on and it is the absence of such, on a consistent basis, that makes me more suspicious! :)

Eg Paxlovid - the new pill. It's a protease inhibtor(like Ivermectin) but both far more expensive and with concerning side effects when taken in conjunction with popular treatments. Eg Statins!

NBC News reports that these medications will require "careful monitoring" by prescribing doctors. This could create problems and make doctors more reluctant to prescribe the meds as the omicron-driven winter wave "pummels" America's supposedly creaking health-care system.

Unfortunately, both Pfizer's and Merck's drugs come with some serious drawbacks, the biggest being that they can cause life-threatening reactions with widely used medications like statins - taken by people with high blood pressure - blood thinners, and even some antidepressants.

What's more, the FDA doesn't recommend Paxlovid for people who have severe liver and kidney disease.


As to the two muppets governing the devolved regions, pretty sure they have already had it! Covid that is, in one variant form, or another.

They'll never get common sense that's for sure!

We are governed by idiots, both sides of the HOUSE are frigthening in their ineptitude. And it only gets worse with the next intake.

And still the British people wont learn and will continue voting for the same parties.

Good news over at Phar - hopefully the positivity will continue.

[emptyend] 29/12/2021 12:51

I'd agree with that Geck. Clearly the press always pick up the most scaremongering scenarios - Beth Rigby, Peston etc are employed only for their enthusiastic distribution of propaganda. When I said "they'll all get it", I meant Covid - not get common sense (clearly that is beyond Sturgeon/Drakeford)...;-)

[geckotheglorious] 29/12/2021 12:46

EE

These "scenarios" need to have a probability attached.They were the most extreme outcomes,chance of which was exceedingly LOW. Yet ask most members of public and they'd tell you they were under the impression that was the most likely" outcome.

As I said, these modellers need to be mosre honest and say what the likelihood of their "scenario" occurring actually is.

All they are doing is fearmongering and scaring the populace. Perhaps that is the idea!

"I’m happy to live in England, rather than live under the jackboots of the maniac control-freaks in Cardiff and Edinburgh. They’ll all get it eventually"

Likewise, and one hopes so. I'm sceptical they will, expecially Sturgeon.

[the real lozan] 29/12/2021 12:41

"I’m happy to live in England,"
.
I TOO am more than happy you live in England,

[emptyend] 29/12/2021 12:22

Nonsense. Such scenarios (NOT forecasts, note) were "do nothing" scenarios. AS A RESULT of encouraging people to be more cautious and taking some small measures to require more caution, the rate of infection has been reduced from earlier expectations. Exactly what one would expect/hope.I went to a Premiership football match yesterday - certainly not a full ground....maybe 15% off capacity, thanks to family commitments, live TV coverage and probably some caution. Covid passports (negative LFT for unjabbed) flashed, mask wearing reasonably complied with (unlike early Dec!) as requested; nobody that concerned.....though a 3-0 win helped :-)I'm happy to live in England, rather than live under the jackboots of the maniac control-freaks in Cardiff and Edinburgh. They'll all get it eventually.

[marcusl2] 29/12/2021 09:48

The ability to increase the potential therapeutic properties of any antibody would therefore be seen as highly advantageous. Scancell has used its AvidiMab™ technology to increase the avidity of its TaG antibodies, and these are currently being evaluated for the treatment of cancer. They are also being developed as antibody-drug conjugates (ADC).3



Professor Lindy Durrant, Chief Scientific Officer of Scancell and Corresponding Author, commented:



"We are pleased to have our work published in the prestigious, peer reviewed journal, Cancer Research. Our AvidiMab™ technology increases the avidity of human antibodies by promoting non-covalent Fc-Fc interactions. This modification also causes direct killing of cancer cells by our glycan targeting antibodies, and therefore we believe this technology has the ability to create superior candidates for cancer immunotherapy."

[marcusl2] 29/12/2021 09:29

Just into phase I

Legochem licenses out ADC to Iksuda in $1B deal
Dec. 28, 2021

By Gina Lee
Legochem Biosciences Inc. has licensed out its antibody-drug conjugate (ADC) LCB-14 to Iksuda Therapeutics Ltd. in the duo’s latest deal that is worth $1 billion. Daejeon, South Korea-based Legochem will receive $50 million in an up-front payment and near-term milestones, and up to $950 million in developments, regulatory and commercial milestones.

[marcusl2] 28/12/2021 19:52

Bermudashorts

12th Annual
Driving Clinical Success in Antibody Drug Conjugates
Creating the Magic Bullet
MAY 5 - 6, 2022 | HYNES CONVENTION CENTER, BOSTON, MA | EDT


4:20 pm
Multi-Functional, Multi-Targeting Anti-Glycan Monoclonal Antibodies


Lindy G. Durrant, PhD, CSO, Scancell Ltd.
Glycans are excellent tumor targets. Notably, the same glycan expressed on a range of glycoproteins/lipids allows mAbs to target multiple antigens some of which can internalize whilst others are retained on the cell surface. Our mAbs can be potent ADCs but also retain ADCC/CDC activity and can cause membrane perturbation resulting in direct cell lysis. Additionally, Avidimab increases the avidity of any mAb and results in improved tumor killing.

www.pegsummit.com/antibody-drug-conjugates

[geckotheglorious] 28/12/2021 13:57

Slightly concerning...
Small sample size autopsy side..

Dr. Sucharit Bhakdi - Autopsy results demonstrate severe auto-immune attack as vaccine consequence



On COVID vaccines: why they cannot work, and irrefutable evidence of their causative role in deaths after vaccination

[wigwammer] 28/12/2021 12:04

If ivermectin met the required efficacy standards, it would be approved, just like dexamethasone has been. But it's great watching the fragile conspiracy believers repeatedly demonstrate - in the clearest fashion - why the vast majority pay no attention to them.